The Future of Lethal Injection Is Being Debated at the Supreme Court. Read These 6 Stories Now.

<a href="http://www.istockphoto.com/portfolio/davidhills#58caa7c">David Hills</a>/iStock

Fight disinformation. Get a daily recap of the facts that matter. Sign up for the free Mother Jones newsletter.


Same-sex marriage is not the only major item on the Supreme Court’s docket this week: Today, the court will begin considering the future of a drug used in lethal injections. The suit, Glossip v. Gross, was brought by three Oklahoma inmates sentenced to death and challenges the use of the sedative Midazolam. The inmates’ lawyers argue that the drug—used in the botched execution of Clayton Lockett, who gasped for air and writhed in pain for a prolonged period as he was put to death—violates the Eighth Amendment’s protection from cruel and unusual punishment.

While only four states currently administer Midazolam, a Supreme Court ruling upholding its use could lead more states to employ the drug in executions. An opposite ruling could make lethal injection, and death penalty execution in general, rarer than it is now. Outlawing Midazolam, one of the few available lethal injection drugs, could leave states without any viable alternatives. Ahead of the oral arguments, read up on Mother Jones‘ best coverage of lethal injection and death penalty issues.

ONE MORE QUICK THING:

Or at least we hope. It’s fall fundraising time, and we’re trying to raise $250,000 to help fund Mother Jones’ journalism during a shorter than normal three-week push.

If you’re reading this, a fundraising pitch at the bottom of an article, you must find our team’s reporting valuable and we hope you’ll consider supporting it with a donation of any amount right now if you can.

It’s really that simple. But if you’d like to read a bit more, our membership lead, Brian Hiatt, has a post for you highlighting some of our newsroom's impressive, impactful work of late—including two big investigations in just one day and covering voting rights the way it needs to be done—that we hope you'll agree is worth supporting.

payment methods

ONE MORE QUICK THING:

Or at least we hope. It’s fall fundraising time, and we’re trying to raise $250,000 to help fund Mother Jones’ journalism during a shorter than normal three-week push.

If you’re reading this, a fundraising pitch at the bottom of an article, you must find our team’s reporting valuable and we hope you’ll consider supporting it with a donation of any amount right now if you can.

It’s really that simple. But if you’d like to read a bit more, our membership lead, Brian Hiatt, has a post for you highlighting some of our newsroom's impressive, impactful work of late—including two big investigations in just one day and covering voting rights the way it needs to be done—that we hope you’ll agree is worth supporting.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate